Global Veterinary Vaccines Market - 2024-2033

Publisher DataM Intelligence 4Market Research LLP

Published Mar 12, 2026

Length 243 Pages

SKU # DTAM21132078

Description

Global Veterinary Vaccines Market Overview:
The Global Veterinary Vaccines Market was valued at US$ 11.5 Billion in 2024 and is anticipated to reach US$ 23.4 Billion by 2033, at a CAGR of 0.082 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Global Veterinary Vaccines Market.

This report delivers a comprehensive overview of the Global Veterinary Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Veterinary Vaccines Market. The Global Veterinary Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Global Veterinary Vaccines Market Scope:
By Animal Type
• Livestock
• Companion
• Aquaculture Vaccines
• Others

By Product
• Traditional Vaccines
• Advanced Vaccines

By Route of Administration
• Subcutaneous
• Intramuscular
• Oral
• Intranasal
• Intraocular
• Others

By End User
• Veterinary Hospitals
• Veterinary Clinics
• Retail Pharmacies
• E-commerce
• Others

By Disease Indication
• Foot-and-Mouth Disease (FMD)
• Newcastle
• Porcine Reproductive and Respiratory Syndrome
• Avian Influenza
• Canine Parvovirus
• Brucellosis
• Rabies
• Others

Key Players
• Merck & Co., Inc.
• Zoetis Services LLC
• Ceva.
• Boehringer Ingelheim International GmbH
• Elanco
• Virbac
• Biogénesis Bagó
• Neogen Corporation
• Bimeda Biologicals

Major Highlights
This report delivers a comprehensive overview of the Global Veterinary Vaccines Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Global Veterinary Vaccines Market. The Global Veterinary Vaccines Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Definition and Overview: 1.1. Study Objectives; 1.2. Market Definition; 1.3. Market Scope; 1.4. Stakeholder Analysis; 1.5. Currency Considered; 1.6. Study Period
2. Executive Summary: 2.1. Key Takeaways; 2.2. Top To Bottom Analysis; 2.3. Market Share Analysis; 2.4. Data Points from Key Primary Interviews; 2.5. Data Points from Key Secondary Databases; 2.6. Market Snapshot; 2.7. Geographical Snapshot
3. Dynamics: 3.1. Impacting Factors; 3.1.1. Drivers; 3.1.1.1. Increasing prevalence of zoonotic and livestock diseases driving demand for preventive vaccination; 3.1.1.2. Rising threat of zoonotic disease transmission between animals and humans, accelerating preventive vaccination adoption; 3.1.1.3. Increasing investments in advanced veterinary biologicals, including recombinant and vector-based vaccines; 3.1.2. Restraints; 3.1.2.1. Complex cold-chain and storage requirements limiting vaccine accessibility in rural livestock regions; 3.1.2.2. Variability in vaccination compliance among small-scale livestock farmers affecting market penetration; 3.1.3. Opportunity; 3.1.3.1. Advancements in biotechnology enabling development of recombinant and next-generation biological vaccines; 3.1.3.2. Expansion of vaccination programs in emerging markets with growing livestock populations; 3.1.4. Trends; 3.1.4.1. Increasing adoption of recombinant and genetically engineered veterinary vaccines; 3.1.4.2. Growing focus on disease prevention strategies to reduce antimicrobial resistance in animal health; 3.1.5. Impact Analysis
4. Industry Analysis: 4.1. Porter's Five Force Analysis – Global Veterinary Vaccines Market; 4.2. Geopolitical & Supply Chain Exposure; 4.2.1. Biological raw material sourcing and antigen supply concentration; 4.2.2. Trade policies, animal health regulations, and livestock disease outbreak risks; 4.3. Social & Animal Health Factors; 4.3.1. Veterinarian vaccination recommendations and livestock health management practices; 4.3.2. Livestock farmer adoption and compliance with vaccination programs; 4.3.3. Increasing companion animal healthcare awareness; 4.3.4. Growing focus on zoonotic disease prevention and animal welfare; 4.4. Economic Factors; 4.4.1. Rising investment in animal healthcare infrastructure; 4.4.2. Cost sensitivity among livestock producers and vaccination program budgets; 4.5. Pricing Analysis; 4.5.1. Branded biological vaccines vs generic veterinary vaccine pricing dynamics; 4.6. Regulatory Analysis; 4.6.1. Veterinary vaccine approval pathways and regulatory requirements; 4.6.2. Post-market surveillance and veterinary pharmacovigilance; 4.6.3. GMP compliance and quality control in biological vaccine manufacturing; 4.6.4. Regional regulatory authorities and harmonization across global markets; 4.7. Go-To-Market (GTM) Strategy; 4.7.1. Veterinary hospitals, livestock farms, and agricultural distribution networks; 4.8. Innovation & R&D Trends; 4.8.1. Development of recombinant and next-generation biological vaccines; 4.8.2. Increasing focus on multivalent and combination veterinary vaccines; 4.9. Sustainability and ESG Analysis; 4.9.1. Responsible biological material sourcing and sustainable livestock disease management; 4.10. Veterinary Vaccine Ecosystem Participants; 4.10.1. Veterinary vaccine manufacturers; 4.10.2. Biotechnology and biological research companies; 4.10.3. Veterinary distributors and animal health service providers; 4.10.4. Contract manufacturing organizations for biological products; 4.10.5. Livestock producers and veterinary healthcare providers; 4.11. Buyer Decision Criteria & Adoption Drivers; 4.11.1. Vaccine efficacy and disease prevention effectiveness; 4.11.2. Regulatory approval and safety profile; 4.11.3. Cost-effectiveness and vaccination program scalability; 4.11.4. Availability across livestock and companion animal disease segments; 4.12. DMI Opinion – Strategic Outlook for the Global Veterinary Vaccines Market
5. By Animal Type: 5.1. Introduction; 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type; 5.1.2. Market Attractiveness Index, By Animal Type; 5.2. Livestock *; 5.2.1. Introduction; 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 5.2.3. Cattle; 5.2.4. Swine; 5.2.5. Poultry; 5.2.6. Others; 5.3. Companion; 5.3.1. Canine; 5.3.2. Feline; 5.4. Aquaculture Vaccines; 5.5. Others
6. By Product: 6.1. Introduction; 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 6.1.2. Market Attractiveness Index, By Product; 6.2. Traditional Vaccines*; 6.2.1. Introduction; 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 6.2.3. Live Attenuated; 6.2.4. Inactivated / Killed; 6.2.5. Toxoid; 6.3. Advanced Vaccines; 6.3.1. Recombinant; 6.3.2. Subunit and Conjugate; 6.3.3. Vector-Based; 6.3.4. Nucleic Acid; 6.3.4.1. DNA; 6.3.4.2. mRNA
7. By Route of Administration: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 7.1.2. Market Attractiveness Index, By Route of Administration; 7.2. Subcutaneous*; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Intramuscular; 7.4. Oral; 7.5. Intranasal; 7.6. Intraocular; 7.7. Others
8. By End User: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User; 8.1.2. Market Attractiveness Index, By End User; 8.2. Veterinary Hospitals*; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Veterinary Clinics; 8.4. Retail Pharmacies; 8.5. E-commerce; 8.6. Others
9. By Disease Indication: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication; 9.1.2. Market Attractiveness Index, By Disease Indication; 9.2. Foot-and-Mouth Disease (FMD)*; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Newcastle; 9.4. Porcine Reproductive and Respiratory Syndrome; 9.5. Avian Influenza; 9.6. Canine Parvovirus; 9.7. Brucellosis; 9.8. Rabies; 9.9. Others
10. By Region: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type; 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User; 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication; 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.2.8.1. US; 10.2.8.2. Canada; 10.2.8.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type; 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User; 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication; 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.3.8.1. Germany; 10.3.8.2. United Kingdom; 10.3.8.3. France; 10.3.8.4. Italy; 10.3.8.5. Spain; 10.3.8.6. Netherlands; 10.3.8.7. Switzerland; 10.3.8.8. Sweden; 10.3.8.9. Norway; 10.3.8.10. Denmark; 10.3.8.11. Belgium; 10.3.8.12. Poland; 10.3.8.13. Austria; 10.3.8.14. Ireland; 10.3.8.15. Portugal; 10.3.8.16. Greece; 10.3.8.17. Finland; 10.3.8.18. Rest of Europe; 10.4. Latin America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type; 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User; 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication; 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.4.8.1. Brazil; 10.4.8.2. Argentina; 10.4.8.3. Mexico; 10.4.8.4. Chile; 10.4.8.5. Colombia; 10.4.8.6. Peru; 10.4.8.7. Rest of Latin America; 10.5. Asia-Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type; 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User; 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication; 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.5.8.1. China; 10.5.8.2. Japan; 10.5.8.3. India; 10.5.8.4. South Korea; 10.5.8.5. Australia; 10.5.8.6. New Zealand; 10.5.8.7. Singapore; 10.5.8.8. Malaysia; 10.5.8.9. Thailand; 10.5.8.10. Indonesia; 10.5.8.11. Vietnam; 10.5.8.12. Philippines; 10.5.8.13. Taiwan; 10.5.8.14. Rest of Asia Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type; 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product; 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User; 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication; 10.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.6.8.1. Saudi Arabia; 10.6.8.2. United Arab Emirates; 10.6.8.3. Qatar; 10.6.8.4. Kuwait; 10.6.8.5. Oman; 10.6.8.6. Bahrain; 10.6.8.7. South Africa; 10.6.8.8. Egypt; 10.6.8.9. Nigeria; 10.6.8.10. Morocco; 10.6.8.11. Rest of Middle East & Africa
11. Competitive Landscape Analysis: 11.1. Competitive Scenario; 11.2. Market Positioning/Share Analysis; 11.3. Mergers and Acquisitions Analysis; 11.4. Partner Identification Analysis; 11.5. Investment & Funding Landscape; 11.6. Strategic Alliances & Innovation Pipelines
12. Company Profiles: 12.1. Merck & Co., Inc.*; 12.1.1. Company Overview; 12.1.2. Product Portfolio; 12.1.3. Revenue Analysis; 12.1.4. Pricing Analysis; 12.1.5. SWOT Analysis; 12.1.6. Recent Developments; 12.1.6.1. Major Deals; 12.1.6.2. M&A; 12.1.6.3. Collaboration; 12.1.6.4. Acquisition; 12.1.6.5. Joint Ventures; 12.1.6.6. Innovations; 12.1.7. Recent News; 12.1.7.1. Events; 12.1.7.2. Conferences; 12.1.7.3. Symposiums; 12.1.7.4. Webinars; 12.2. Zoetis Services LLC; 12.3. Ceva.; 12.4. Boehringer Ingelheim International GmbH; 12.5. Elanco; 12.6. Virbac; 12.6.1. Phibro Animal Health Corporation; 12.7. Biogénesis Bagó; 12.8. Neogen Corporation; 12.9. Bimeda Biologicals (LIST NOT EXHAUSTIVE)
13. Global Veterinary Vaccines Market – Research Methodology: 13.1. Research Data; 13.1.1. Secondary Data; 13.1.2. Primary Data; 13.1.3. CAGR Analysis; 13.2. Market Size Estimation Methodology; 13.2.1. Bottom-Up Approach; 13.2.2. Top-Down Approach; 13.3. Market Breakdown & Data Triangulation; 13.4. Research Assumptions; 13.5. Limitations
14. Appendix: 14.1. About Us and Services; 14.2. Contact Us

Pricing

Currency Rates

Single User Email from Publisher $2,999
Global Site License Email from Publisher $4,900

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now